1. INTRODUCTION {#sec1}
===============

Rheumatoid Arthritis (RA) is a chronic and systemic disease that affects the joints, connective tissues, muscles, tendons and fibrous tissues, and in addition to pain, causing deformations in the bony-cartilaginous structure. The prevalence is approximately 1% of the world population \[[@r1]\]. The RA is mediated by Th1/Th17 cells, where TNF, IL-6 and IL-17 cytokines are key components in the RA pathogenesis \[[@r2]\].

Cardiovascular disease (CVD) represents one of the most frequent comorbidities in RA patients, and it is responsible for increasing the mortality of this population up to twice \[[@r3], [@r4]\]. A recent study indicates that in several countries, cardiovascular diseases remain the main comorbidities found in patients with RA (4). The prevalence of systemic arterial hypertension (SAH) is high in patients with RA, ranging from 53% -73% \[[@r5]\]. When comparing this percentage with the general population, this index is no more than 23% \[[@r5]\]. It is also known that hypertension is associated with the presence of asymptomatic lesions in RA patients regardless of the level of inflammatory activity \[[@r6]\]. With this, the need has become evident for a better understanding and attention at the time medication is prescribed for patients with RA \[[@r7]\].

Recent studies have highlighted the role of inflammation in the development of hypertension. Mechanisms of innate immunity, effector and regulatory T cells, and costimulatory molecules seem to be involved in the ethiopatogenesis of hypertension, interacting mostly with the Renin-Angiotensin-Aldosterone System (RAAS). This is the main responsible agent for the regulation of blood pressure and water balance \[[@r8]\]. It is suggested that the RAAS has a relationship with the activation of the immune system once there is more circulating aldosterone, activating angiotensin type 1 (AT1) receptors in immune cells such as lymphocytes and monocytes \[[@r9], [@r10]\].

There is a consensus of the Brazilian Society of Rheumatology regarding the treatment of comorbidities in RA. For SAH, the indicated treatment is composed of Angiotensin Converting Enzyme (ACE) inhibitors and/or angiotensin II receptor blockers (ARBs), preferably \[[@r11]\].

In a study with rats on an experimental autoimmune myocarditis and treated with Valsartan, there was a suppression of Th1 serum cytokine levels and significant positive regulation of Th2 cytokines, demonstrating the benefits of Valsartan as a balance modulator of Th subgroups \[[@r12]\]. Some studies point to Enalapril as a weak immunomodulator with few effects on the cytokine production by macrophages \[[@r13], [@r14]\]. On the other hand, Losartan presented better results being able to reduce IL-6 levels and increasing TGF-β production in patients with cardiovascular diseases \[[@r15], [@r16]\].

Valsartan and Telmisartan were tested in type II diabetes with immune effects, perhaps binding to Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) \[[@r17]\], and Valsartan is able to slow down the progression of chronic kidney disease \[[@r18]\]. In adult patients with Marfan syndrome, Losartan as treatment reduced the rate of dilation of the aortic arch \[[@r19]\]. In addition, Losartan and Enalapril were capable of reducing the expression of IL-1β in macrophages \[[@r20]\] and polymorphonuclear leukocytes from patients with essential hypertension \[[@r21]\].

Clearly ARBs and ACEs have different effects besides blood pressure control, but their immunomodulatory effects in PBMCs from RA patients are still unclear. The objective of the present study was to evaluate the effects of Enalapril, Losartan and Valsartan on the production of IL-2, IL-10, IL-6, TNF, IFN-γ, IL-17A, IL-17F and IL-22 cytokines in PBMCs of patients with rheumatoid arthritis and evaluate this modulation with disease activity.

2. METHODS {#sec2}
==========

2.1. Volunteers Recruitment {#sec2.1}
---------------------------

Sixteen RA patients were invited and recruited from Rheumatology Division at Clinics Hospital -- Federal University of Pernambuco, Brazil, to participate. Demographic and clinical parameters were collected from all patients by questionnaire (Table **[1](#T1){ref-type="table"}**). DAS28 and CDAI were measured and criteria for RA classification \[[@r22], [@r23]\]. A DAS28 lower than 3.2 implied low disease activity, between 3.2--5.1 implied moderate and higher than 5.1 meant high disease activity, while CDAI less than 2.8 implied clinical remission, lower than 10 implied mild activity, between 10--22 implied moderate and finally higher than 22 score implied severe activity.

The presence of other rheumatic diseases, cardiovascular, endocrine and thyroid, immunomodulated and cancer diseases were exclusion criteria for all volunteers. Moreover, being under biological, immunomodulatory or antihypertensive treatments also were exclusion criteria. The study was approved by the Federal University of Pernambuco (UFPE) ethics committee (CAAE: 53555116.0.0000.5208).

2.2. Antihypertensives Drugs {#sec2.2}
----------------------------

We used 3 antihypertensive drugs. Two of them are ARBs, Losartan and Valsartan and an ACE Enalapril. All medicines were chosen because they are widely used in cardiovascular diseases around the world. For a better understanding, the drugs were named using the initials: Enalapril (E), Losartan (L) and Valsartan (V).

2.3. PBMCs Sample for Immunomodulatory Experiments {#sec2.3}
--------------------------------------------------

Peripheral Blood Mononuclear Cells (PBMC) from RA volunteers were obtained using a heparinized tube and isolated by density-gradient centrifugation with Ficoll-Hypaque (GE Healthcare). Therefore, $1 \times 10^{6}$ cells/ml were disposed in RPMI-1640 media (Gibco) supplemented with 10% fetal bovine serum (Gibco), HEPES 10 mM (Gibco) and penicillin/streptomycin 200 U/ml (Gibco).

Cells were stimulated using anti-CD3 and anti-CD28 Monoclonal Antibodies (mAB) (eBioscience) - once RA is a T-lymphocyte-mediated disease -- \[[@r24], [@r25]\] in the presence or absence of Losartan, Valsartan and Enalapril at 100μM. Methylprednisolone at 100μM was used as a standard drug. Cells were incubated for 48hours at 37°C in humidified 5% CO2 incubator, therefore the supernatant was collected and stocked at -80°C for posterior dosages.

2.4. Cytokine Measurement {#sec2.4}
-------------------------

Enzyme-linked Immunosorbent Assay (ELISA) kits according to the manufacturer's instructions determined Cytokines present in the supernatants. The detection limits for TNF, IL-10, IL-6 and IFN-γ (BD Biosciences), IL-2, IL-17A, IL-17F and IL-22 (eBioscience) were 3.90, 3.90, 4.68, 4.68, 1.95, 3.90, 15.62 and 7.81 pg/ml, respectively.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The Wilcoxon and Student's t tests were used for statistical analysis and *p* values \< 0.05 were statistically significant. Values are expressed as the median, maximum and minimum for supernatant dosages and mean ± Standard Deviation (SD) for demographic parameters. All quantitative data was plotted with GraphPad Prism^®^ 6.01.

3. RESULTS {#sec3}
==========

3.1. RA Patients Parameters {#sec3.1}
---------------------------

A total of 16 patients fulfilled four or more American College of Rheumatology (ACR) 2010 diagnostic criteria \[[@r26]\]. Individual disease activity was quantified using the DAS28 \[[@r23]\] and CDAI \[[@r22]\]. Demographic, clinical and laboratory data were collected, and these results are shown in Table **[1](#T1){ref-type="table"}**.

3.2. Enalapril, Losartan and Valsartan Inhibiting Inflammatory Cytokines {#sec3.2}
------------------------------------------------------------------------

The first step was to evaluate the cytotoxicity of the antihypertensives Enalapril (E), Losartan (L) and Valsartan (V) in PBMC to confirm a non-toxic concentration. We tested five different concentrations (10, 25, 50, 75 and 100µM) in triplicate of concentration and triplicate of experiment. None of the drugs tested showed toxicity at the used concentration and viability was higher than 98% (data not shown) and the 100μM was used for tests.

Cytokines levels can be seen in Fig. (**[1](#F1){ref-type="fig"}**). Median, maximum and minimum expresses the results. There was a significant decrease in IFN-γ by Enalapril at 100µM \[2988.53 (18895.29-4.68)\] (*p*= 0.0302) compared to the stimulated condition \[5157.895 (63637.65-155.29)\] and IL-22 \[13.65 (195.58-7.81)\] compared to mAB stimulation only \[100.84 (218.67-9.50)\] (*p*=0.0161).

Losartan had immunomodulatory effects reducing IFN-γ, IL-6, IL-17F and IL-22. For IFN-γ, there was significant decrease by Losartan at 100μM \[2252.6 (20461.1-4.6)\] compared to the stimulated condition (p = 0.0181). For IL-6 it was \[2154.2 (8480.8-4.6)\] compared to the stimulated condition \[3178.60 (10064.8-136.4)\] (*p* = 0.0056). We also found a significant reduction in IL-17F by Losartan \[457.6 (1239.8-129.6)\] compared to the stimulated condition \[1181.5 (3836.5-236.0)\] (*p* = 0.0046). Finally, IL-22 had a significant reduction by Losartan in RA group \[100.4 (175.5-7.8)\] compared to the stimulated condition \[100.84 (218.67-9.50)\] (*p* = 0.0234). Valsartan showed no significant association.

3.3. Effect of Antihypertensive Drugs on Cytokine Profile Association with Disease Activity of RA {#sec3.3}
-------------------------------------------------------------------------------------------------

Subsequently, we analyzed the effect of Enalapril, Losartan and Valsartan on the cytokine profile and evaluated if there was any correlation with disease activity measured by DAS28 and CDAI. There was significant association for IFN-γ, IL-10, IL-17F and IL-22 according DAS28 \< 3.2 (*p* = 0.0391; 0.0313; 0.0156; 0.0156 respectively) and for DAS28 \> 3.2 in IL-22 reduction (*p* = 0,0313) after 100μM of Losartan treatment (Fig. **[2A](#F2){ref-type="fig"}**). In concurrence, there was significant association for IFN-γ, IL-6 and IL-22 also according CDAI \< 10 (*p* = 0.0391; 0.0391; 0.0313 respectively) after 100μM of Losartan treatment (Fig. **[2B](#F2){ref-type="fig"}**). No association was found in Enalapril and Valsartan treatments.

It was observed that RA patients with severe disease had a worse response to the Losartan in reducing cytokines levels. The same profile was observed for other cytokines, however without significance.

4. DISCUSSION {#sec4}
=============

Experimental *in vitro* and *in vivo* studies have strongly demonstrated that antihypertensive drugs have anti-inflammatory and immunomodulatory functions \[[@r8], [@r12], [@r15], [@r27]\]. However, the potential of these drugs in rheumatoid arthritis disease has not yet been demonstrated. We decided to analyze the effect of anti-hypertensive drugs in PBMCs variations corresponding to disease activity by DAS28 and CDAI according to the international criteria.

RA develops and progresses with the immune system imbalance involving defense cells, mainly by B cells and CD4+ T cells and their subgroups. The most involved T helper in RA pathogenesis are Th1 and Th17 and their inflammatory cytokines produced \[[@r28]\]. RA patients generally suffer with cardiovascular diseases - incidence is higher than 70% (5). Immunological markers of inflammation are expressed in higher concentrations in RA patients who have CVC diseases, including highly sensitive C-reactive protein \[[@r29]\].

For SAH in RA, the indicated treatment is composed of ACE and/or ARBs, preferably (11). ACE inhibitors and ARBs are used in the treatment of cardiovascular diseases with good results, including for RA patients \[[@r30]\]. Cardiovascular risk factors and systemic inflammation are associated with the rapid progression of carotid intima-media thickness in RA patients \[[@r31]\]. For this reason, it is necessary to test whether the antihypertensive drugs promote immunomodulation and if one of them can be a first decision for the SAH treatment in RA patients.

Our results show that Losartan at 100µM could significantly reduce IFN-γ, IL-6, IL-17F, IL-22 cytokine levels secreted by PBMCs in RA cultures. The other antihypertensive drugs tested, Enalapril and Valsartan had few or no immunomodulatory effects on the production of proinflammatory cytokines in PBMCs.

We showed that Losartan consistently reduced IL-17F cytokine levels in a 100µM concentration. In addition, IL-17F correlates with disease severity by DAS28 and CDAI, Losartan was able to sensitize patients\' cells in remission/mild/moderate RA condition reducing the levels of this cytokine, but no effects were seen in severe score.

Proinflammatory cytokines are involved in RA and aggravate the disease development. One of them is IL-17. IL-17A and IL-17F are highly reported in RA and contribute to the RA pathogenesis \[[@r32]\]. Both IL-17A and IL-17F are present in synovium and aggravate the illness \[[@r28]\]. Accordingly, IL-17F appears as a target in Th17-mediated diseases such as RA \[[@r33], [@r34]\]. That is interesting because although involved in RA, IL-17 also plays a key role in the pathogenesis of arterial hypertension, inducing the production of angiogenic factors and migration of endothelial cells \[[@r35]\]. IL-17A also mediates Angiotensin II (Ang II) induced renal injury and regulates renal sodium transporters, activating a serum and glucocorticoid regulated kinase 1 dependent pathway, and it could cause a sodium and water imbalance and therefore elevating the blood pressure \[[@r35]-[@r37]\]. Reducing IL-17 circulating levels would not only have an improvement in RA but would also benefit hypertensive patients. As we demonstrated, our results show a potential immunoregulation of Losartan in reducing IFN-γ levels. In addition to this Losartan was also able to statistically reduce significant IL-6 levels in PBMC culture from RA patients.

IFN-γ and IL-6 are two inflammatory cytokines with innumerable functions, such as cell proliferation and immune system regulation. IL-6 also is a treatment target for RA \[[@r38]\]. Cell responses from both are activated*via*Janus Kinase/Signal Transducer and Activator of Transcription Proteins (JAK/STAT) pathway \[[@r39]\]. The IFN family is related to the pathogenesis of RA and this is well described \[[@r40], [@r41]\]. This cytokine undoubtedly participates in the joint inflammation promoting cell recruitment and proliferation. IFN-γ is also considered a marker for RA \[[@r42]\]. IFN-γ and IL-6, although distinct, act together and can be produced in parallel in an inflammation site*via*similar transcription factors such as Interferon Regulatory Factor 1 (IRF-1) and intercellular adhesion molecule 1 (ICAM-1) \[[@r43]\]. In addition, IL-6 is also crucial in the pathogenesis of RA \[[@r44]\]. It is correlated with swollen joint count, c-reactive protein levels and associated with DAS28 severity, rheumatoid factor and serology of anti-citrullinated peptide antibodies \[[@r45]\].

Our results suggest that Losartan could significantly reduce the IL-22 levels produced by PBMC from RA patients. IL-22 is a pleiotropic cytokine. It is related to osteoclastogenesis by positively regulating the expression of Receptor Activator of Nuclear factor kappa-Β ligand (RANKL) mediated*via*Mitogen Activated Protein Kinase (MAPK) and Factor Nuclear kappa B - p38 MAPK/NF-κB and JAK-2/STAT-3 - signaling pathways \[[@r46]\]. But at the same time CD4 + Th22 cells are also related to the pathogenesis of RA, contributing to the worsening of this disease \[[@r47]\] by promoting the proliferation of synoviocytes \[[@r48]\], and may become a therapeutic target soon \[[@r49]-[@r51]\]. Few studies have correlated the levels of IL-22 with the RA severity and possible treatments to reduce this cytokine production \[[@r40], [@r52], [@r53]\].

For all cytokines evaluated we observed that patients with severe activity of disease (DAS28 \> 3.2 and CDAI \> 10) respond in worse efficiency to Losartan treatment. Patients in severe conditions probably have their cells sensitized due to an anti-inflammatory treatment and this makes the *in vitro* study harder. As RA is a chronic and degenerative disease, nowadays it is very difficult to recruit patients in severe conditions who are not taking any anti-inflammatory medication. A previously analysis was not performed to affirm if patients who were on Prednisone treatment could be an influencing factor.

Of the three antihypertensive drugs tested, Losartan improved immunomodulatory effects in PBMCs of patients with RA. Probably, this reduction is due to an inhibitory effect of Losartan on NF-κB upregulated in RA patients modulating proinflammatory cytokines \[[@r54], [@r55]\].

CONCLUSION
==========

In conclusion, our findings suggest that the Losartan therapy does modulate IFN-γ, IL-6, IL-17F and IL-22 at 100µM in PBMCs from RA patients according to disease activity. Moreover, none significative immunomodulatory activities were observed with Enalapril or Valsartan at 100µM in cytokine production, suggesting Losartan could be a better option for SAH treatment in RA patients. Further studies are still needed to elucidate the molecular mechanism that Losartan acts in PBMCs.
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###### 

Clinical parameters of RA patients recruited.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristics**\                                                                                                                        **Data**
  **Patients (n = 16)**                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  **Female n**                                                                                                                                14

  **Male n**                                                                                                                                  2

  **Age (years), mean (min-max)**                                                                                                             53 (32 -- 73)

  **Disease Duration (years), mean (range)**                                                                                                  10 (±7,9)

  **DAS28 (%)**\                                                                                                                              \
  **Low Disease Activity (≤3.2)**\                                                                                                            9 (56%)\
  **Moderate and High Disease Activity (\>3.2)**                                                                                              7 (44%)

  **CDAI (%)**\                                                                                                                               \
  **Low Disease Activity (≤ 10)**\                                                                                                            8 (50%)\
  **Moderate and High Disease Activity (\> 10)**                                                                                              8 (50%)

  **Treatment (%)\***\                                                                                                                        \
  **None**\                                                                                                                                   3\
  **Prednisone**\                                                                                                                             9\
  **Methotrexate**\                                                                                                                           11\
  **Leflunomide**                                                                                                                             2

  **ESR mean (range mm/h)**                                                                                                                   16 (±10)

  **Rheumatoid Factor (%)**                                                                                                                   16 (100%)

            **\* Eight patients were on Prednisone and Methotrexate combination and only one on Leflunomide and Methotrexate combination.**   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------
